Back to first-pass browser

First-pass extracted concept

genomic safe harbors

Candidate: concept label2 source documents6 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

GSHs

Extracted Explainers

What the tool is doing

Genomic safe harbors are presented as genomic loci for site-specific CAR transgene integration that support stable, high-level expression without oncogenic disruption. The review frames them as an alternative to semi-random viral integration.

Source 1DOIPubMed

Genomic safe harbors are described as stable genomic regions relevant to site-specific transgene insertion in maize.

Source 2DOIPubMed

Resources required

Use of these loci requires targeted genome engineering approaches for site-directed integration and downstream genomic monitoring. The abstract also notes challenges tied to homology-directed repair and dsDNA donor toxicity.

Source 1DOIPubMed

What problem it solves

They are proposed to mitigate delayed genotoxic risks and secondary primary malignancies associated with random vector insertion near oncogenes or tumor suppressor loci.

Source 1DOIPubMed

They help frame where transgenes can be inserted to support stable elite lines.

Source 2DOIPubMed

What it does not solve

The abstract does not claim that safe-harbor targeting fully removes all editing-related risks, and it explicitly notes residual concerns including off-target damage, dsDNA toxicity, and manufacturing/regulatory challenges.

Source 1DOIPubMed

Alternatives

The abstract contrasts GSH targeting with conventional gamma-retroviral or lentiviral vector manufacturing and mentions emerging precision approaches such as base editing, prime editing, and hybrid nucleases.

Source 1DOIPubMed

Evidence Snippets

This review evaluates genomic safe harbors (GSHs)-such as AAVS1, TRAC, CCR5, ROSA26 and CLYBL-as loci validated for stable, high-level CAR transgene expression without oncogenic disruption.
Evidence 1Source 1DOIPubMedprovenance
the advances made in identifying genomic safe harbors in the maize genome
Evidence 2Source 2DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1design criteriasupports2025Source 1DOIPubMed

Genomic safe harbors meet criteria of being distal from cancer-related genes, resistant to epigenetic silencing, and transcriptionally permissive.

Quoted textsource-backed
GSHs meet stringent criteria: distal from cancer-related genes, resistant to epigenetic silencing, and transcriptionally permissive.
Claim 2limitationsupports2025Source 1DOIPubMed

Current targeted integration approaches still face challenges in homology-directed repair efficiency, residual dsDNA toxicity, and standardizing regulatory frameworks for long-term genomic surveillance.

Quoted textsource-backed
Challenges persist in optimizing homology-directed repair efficiency, mitigating residual dsDNA toxicity, and standardizing regulatory frameworks for long-term genomic surveillance.
Claim 3preclinical outcomesupports2025Source 1DOIPubMed

Preclinical studies demonstrate that site-directed CAR integration into genomic safe harbors preserves antitumor efficacy while eliminating malignant transformation risks.

Quoted textsource-backed
Preclinical studies demonstrate that site-directed CAR integration into GSHs preserves antitumor efficacy while eliminating malignant transformation risks.
Claim 4property assertionsupports2025Source 1DOIPubMed

Genomic safe harbors are described as loci validated for stable, high-level CAR transgene expression without oncogenic disruption.

Quoted textsource-backed
This review evaluates genomic safe harbors (GSHs)-such as AAVS1, TRAC, CCR5, ROSA26 and CLYBL-as loci validated for stable, high-level CAR transgene expression without oncogenic disruption.
Claim 5risk associationsupports2025Source 1DOIPubMed

Emerging reports link CAR-T cell therapy to second primary malignancies including CAR-positive lymphomas and leukemias driven by insertional mutagenesis from semi-random viral vector integration near oncogenes or tumor suppressor loci.

Quoted textsource-backed
emerging reports link this therapy to second primary malignancies, including CAR+ lymphomas and leukemias, driven by insertional mutagenesis from semi-random viral vector integration near oncogenes or tumor suppressor loci
Claim 6safety mechanismsupports2025Source 1DOIPubMed

Conventional CAR-T manufacturing using gamma-retroviral or lentiviral vectors introduces genomic instability through integration into fragile sites or transcriptionally active regions.

Quoted textsource-backed
Conventional CAR-T cell manufacturing, reliant on gamma-retroviral or lentiviral vectors, introduces genomic instability through integration into fragile sites or transcriptionally active regions.